These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cerivastatin and the dissemination of adverse event information. Weaver SJ; Doering PL Ann Pharmacother; 2002 Jun; 36(6):1099-103. PubMed ID: 12058704 [No Abstract] [Full Text] [Related]
43. Remedies needed to address the pathology in reporting adverse reactions and Food and Drug Administration use of reports. Wolfe SM J Gen Intern Med; 2003 Jan; 18(1):72-3. PubMed ID: 12534769 [No Abstract] [Full Text] [Related]
44. A new analytic tool developed to assess safe use recommendations. Cocoros NM; Wagner A; Haynes K; Petrone AB; Fazio-Eynullayeva E; Ding Y; Izem R; Lee JY; Major JM; Nguyen M; Ju J Pharmacoepidemiol Drug Saf; 2019 May; 28(5):649-656. PubMed ID: 30747473 [TBL] [Abstract][Full Text] [Related]
45. The benefits of data mining. Bone A; Houck K Elife; 2017 Aug; 6():. PubMed ID: 28813246 [TBL] [Abstract][Full Text] [Related]
47. The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety. Lo Re V; Strom BL Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):818-25. PubMed ID: 17436357 [TBL] [Abstract][Full Text] [Related]
48. An analysis of Australian adverse drug events. Malpass A; Helps SC; Runciman WB J Qual Clin Pract; 1999 Mar; 19(1):27-30. PubMed ID: 10096721 [TBL] [Abstract][Full Text] [Related]
49. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123 [TBL] [Abstract][Full Text] [Related]
50. The FDA Sentinel Initiative - An Evolving National Resource. Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777 [No Abstract] [Full Text] [Related]
52. Trouble at the FDA: can we fix the problems affecting you and your patients? Henley E J Fam Pract; 2006 Apr; 55(4):301-4. PubMed ID: 16608668 [No Abstract] [Full Text] [Related]
53. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use. Li AS; Pomeranz HD J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718 [No Abstract] [Full Text] [Related]
54. How to evaluate the benefit-risk profile of newly marketed drugs. Naldi L Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357 [No Abstract] [Full Text] [Related]
55. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System. Min J; Osborne V; Kowalski A; Prosperi M Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610 [TBL] [Abstract][Full Text] [Related]
56. Medical device safety: FDA's postmarket transformation initiative. Schultz D Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401 [No Abstract] [Full Text] [Related]
57. Adverse drug events and the Freedom of Information Act: an apple in Eden. Stang PE; Fox JL Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939 [TBL] [Abstract][Full Text] [Related]
58. Adverse drug reporting issues for managers. Sperling RL Home Healthc Nurse Manag; 1999; 3(6):26-9. PubMed ID: 10876507 [No Abstract] [Full Text] [Related]
59. Risk management from an Asian/Pacific Rim regulatory perspective. McEwen J Drug Saf; 2004; 27(8):491-7. PubMed ID: 15154822 [TBL] [Abstract][Full Text] [Related]